Your browser doesn't support javascript.
loading
Virgin Coconut Oil: A Dietary Intervention for Dyslipidaemia in Patients with Diabetes Mellitus.
Setyawati, Andina; Sangkala, Moh Syafar; Malasari, Silvia; Jafar, Nuurhidayat; Sjattar, Elly L; Syahrul, Syahrul; Rasyid, Haerani.
Affiliation
  • Setyawati A; Lecturer of Medical and Surgical Nursing Department of Nursing Faculty, Universitas Hasanuddin, Makassar 90245, Indonesia.
  • Sangkala MS; Lecturer of Medical and Surgical Nursing Department of Nursing Faculty, Universitas Hasanuddin, Makassar 90245, Indonesia.
  • Malasari S; Lecturer of Community, Family, and Gerontology Nursing Department of Nursing Faculty, Universitas Hasanuddin, Makassar 90245, Indonesia.
  • Jafar N; Lecturer of Community, Family, and Gerontology Nursing Department of Nursing Faculty, Universitas Hasanuddin, Makassar 90245, Indonesia.
  • Sjattar EL; Lecturer of Medical and Surgical Nursing Department of Nursing Faculty, Universitas Hasanuddin, Makassar 90245, Indonesia.
  • Syahrul S; Lecturer of Community, Family, and Gerontology Nursing Department of Nursing Faculty, Universitas Hasanuddin, Makassar 90245, Indonesia.
  • Rasyid H; Lecturer of Medicine Faculty, Universitas Hasanuddin, Makassar 90245, Indonesia.
Nutrients ; 15(3)2023 Jan 21.
Article in En | MEDLINE | ID: mdl-36771272
ABSTRACT
Hyperlipidaemia is causally related to coronary artery diseases (CAD) and peripheral artery diseases (PAD) in people with Diabetes Mellitus (DM). An in vivo study confirmed that virgin coconut oil (VCO) could maintain levels of lipids in the blood as effectively as conventional therapy. Therefore, this study aimed to determine the effect of VCO on the lipid profiles and ankle-brachial index (ABI) of patients with DM. In this experimental study with pre- and post-test design and a control group, the participants were selected purposively. The ABI was evaluated on the first visit. Baseline lipid profile readings were taken. Each participant took 1.2 mL/kgBW of VCO daily and divided it into three doses. After 30 days of taking VCO, laboratory examinations and ABI were repeated, and adverse events were evaluated. The dependent t-test and Wilcoxon sign rank test with a significance level of α ≤ 0.05 showed a significant decrease in low-density lipoprotein (LDL) (p = 0.002), a significant increase in high-density lipoprotein (HDL) levels (p = 0.031), a significant decrease in energy intake (p = 0.046) and cholesterol intake (p = 0.023) at the endpoint in the VCO group. In conclusion, this therapy is beneficial for maintaining lipid profile when combined with dietary therapy. Future studies should investigate the duration and dosage of VCO on patients to maintain lipid-linked protein.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus / Hyperlipidemias Limits: Humans Language: En Journal: Nutrients Year: 2023 Document type: Article Affiliation country: Indonesia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus / Hyperlipidemias Limits: Humans Language: En Journal: Nutrients Year: 2023 Document type: Article Affiliation country: Indonesia